Prevalence of chronic kidney disease according to the retrospective cohort study “CKD epidemiology” (Kirov City)

The Study aimed to describe the available clinical and demographic characteristics of patients with CKD, to assess its occurrence by primary referral, and to analyze the clinical outcomes and current treatment of CKD. Material and methods: a retrospective cohort clinical study (protocol identification number: EVS-20-01115) was carried out. Electronic databases of medical records of patients undergoing outpatient treatment in the city of Kirov were examined. The inclusion criteria were diagnosed CKD or the presence of one or more changes in the structure or function of the kidneys associated with the development of CKD, determined for more than 3 months. Results: the occurrence of CKD in a cohort of outpatients from three medical institutions in the city of Kirov was 8.7% of the total number of outpatients. The structure of CKD stages demonstrated a low degree of detectability of CKD stages 1-2; CKD C2 and C3 were the most common (76.5%), while the prevalence of C1 was only 10.2%. Proteinuria was observed in 25% of patients with CKD, i.e. 1.83% of the number of patients in the database. Albuminuria was found rarely, in 7.39% of the total number of patients with abnormalities of the kidneys structure or function and 11.91% of patients with an established diagnosis of CKD. As a decrease in GFR was observed in 89.8% of CKD cases, and proteinuria in 25% of cases a decrease in GFR was a more frequent sign of CKD than proteinuria in the registered CKD cases by primary referral. Arterial hypertension, cerebrovascular diseases, and diabetes mellitus were widespread in patients with CKD. The most commonly prescribed drugs for CKD were aCEI and ARBs prescribed in 81.8% of cases. Conclusion: the analysis made clear the need for earlier detection of CKD C1-C2 and such diseases as diabetes mellitus and hypertension, which are the main causes of CKD (Trial is funded by Astra Zeneca company (LLC "AstraZeneca pharmaceuticals"), protocol EVS-20-01115).

хроническая болезнь почек, протеинурия, скорость клубочковой фильтрации, chronic kidney disease, proteinuria, glomerular filtration rate

1. Li PK, Garcia-Garcia G, Lui SF, et al. Reprint of: Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Nephrol Ther. 2020 Jul;16(4):211-216. doi: 10.1016/j.nephro.2020.04.001.

2. Foreman K.J., Marquez N., Dolgert A. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018. 392(10159):2052-2090.

3. Gandjour A., Armsen W., Wehmeyer W. et al. Costs of patients with chronic kidney disease in Germany. PLoS One. 2020. 15(4):0231375. doi:10.1371/journal.pone.0231375

4. Дудко М.Ю., Котенко О.Н., Шутов Е.В., Васина Н.В. Эпидемиология хронической болезни почек среди жителей города Москвы. Клиническая нефрология. 2019. 3:37-41.

5. Bikbov M.M., Zainullin R.M., Kazakbaeva G.M. et al. Chronic kidney disease in Russia: the Ural eye and medical study. BMC Nephrol. 2020. 21(1):198. doi:10.1186/s12882-020-01843-4

6. Шилов Е.М., Котенко О.Н., Шилова М.М. и соавт. Состояние нефрологической службы: заместительная почечная терапия в Российской Федерации в период с 2015 по 2019 г. Клиническая нефрология. 2020.1:6-17.

7. Борисов А.Г., Потехин Н.П., Корякин С.В. Выявляемость хронической болезни почек у военнослужащих по результатам военно-врачебной экспертизы в главном военном госпитале. Нефрология. 2019.23(5):21-22.

8. Хамидова З.Н., Рахматова Р.М., Шаджанова Н.С. Частота распространения гипертонической нефропатии и особенности ее течения у женщин фертильного возраста с артериальной гипертензией. Вестник совета молодых ученых и специалистов Челябинской области. 2016;5(4):54-58.

9. Соловьянова Е.Н., Филина Л.В., Поздышева Т.Е. Хроническая болезнь почек в Нижегородской области и перспективы улучшения качества помощи больным на додиализных стадиях. Кардиоваскулярная терапия и профилактика. 2014;13(S2):108.

10. Федеральная Служба Государственной Статистики https://rosstat.gov.ru/dbscripts/munst/munst33/DBInet.cgi.